PMID- 32598747
OWN - NLM
STAT- MEDLINE
DCOM- 20200729
LR  - 20200729
IS  - 0040-3660 (Print)
IS  - 0040-3660 (Linking)
VI  - 91
IP  - 8
DP  - 2019 Aug 15
TI  - [Current advances in the treatment of gastroesophageal reflux disease: a focus on 
      esophageal protection].
PG  - 4-11
LID - 10.26442/00403660.2019.08.000387 [doi]
AB  - Gastroesophageal reflux disease (GERD) is characterized by high morbidity and a 
      significant decrease in the quality of life of patients, and is a major risk 
      factor for esophageal adenocarcinoma. Nowadays, antisecretory therapy with proton 
      pump inhibitors (PPI) is the "gold standard" of conservative treatment of GERD, 
      but in some cases this therapy is unsuccessful. According to various studies, the 
      prevalence of refractory GERD can reach 30-40%. The latest scientific data in the 
      field of genetics and pathophysiology of GERD demonstrate that a disruption of 
      the barrier function of the esophageal mucosa and an increase of its permeability 
      can be the leading causes of refractoriness. Thus, the optimal therapy for 
      patients with GERD should not only suppress the secretion of hydrochloric acid, 
      but also restore the barrier function of the mucous membrane, providing an 
      esophagoprotective effect. To achieve these goals, Alfasoxx was developed, which 
      consists of a mixture of low molecular weight hyaluronic acid and low molecular 
      weight chondroitin sulfate dissolved in a bioadhesive carrier (poloxamer 407). 
      The clinical efficacy of this product has been confirmed by three prospective, 
      randomized, placebo - controlled trials. Alfasoxx has a healing and restorative 
      effect towards the esophageal epithelium and due to high ability for bioadhesion 
      provides long - term protection of the mucous membrane of the esophagus. 
      Combination therapy for GERD with the use of PPI and an esophagoprotector offers 
      new perspectives for the treatment of patients with GERD.
FAU - Maev, I V
AU  - Maev IV
AD  - Yevdokimov Moscow State University of Medicine and Dentistry.
FAU - Andreev, D N
AU  - Andreev DN
AD  - Yevdokimov Moscow State University of Medicine and Dentistry.
FAU - Kucheryavyy, Y A
AU  - Kucheryavyy YA
AD  - Yevdokimov Moscow State University of Medicine and Dentistry.
FAU - Shaburov, R I
AU  - Shaburov RI
AD  - Yevdokimov Moscow State University of Medicine and Dentistry.
LA  - rus
PT  - Journal Article
DEP - 20190815
PL  - Russia (Federation)
TA  - Ter Arkh
JT  - Terapevticheskii arkhiv
JID - 2984818R
RN  - 0 (Proton Pump Inhibitors)
SB  - IM
MH  - *Gastroesophageal Reflux/drug therapy
MH  - Humans
MH  - Prospective Studies
MH  - *Proton Pump Inhibitors/therapeutic use
MH  - *Quality of Life
OTO - NOTNLM
OT  - Alfasoxx
OT  - Esoxx
OT  - chondroitin sulfate
OT  - esophagoprotective
OT  - gastroesophageal reflux disease
OT  - hyaluronic acid
OT  - refractoriness
OT  - treatment
EDAT- 2020/07/01 06:00
MHDA- 2020/07/30 06:00
CRDT- 2020/06/30 06:00
PHST- 2020/04/16 00:00 [received]
PHST- 2020/06/30 06:00 [entrez]
PHST- 2020/07/01 06:00 [pubmed]
PHST- 2020/07/30 06:00 [medline]
AID - 10.26442/00403660.2019.08.000387 [doi]
PST - epublish
SO  - Ter Arkh. 2019 Aug 15;91(8):4-11. doi: 10.26442/00403660.2019.08.000387.